PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer

NCT ID: NCT03638297

Last Updated: 2023-10-17

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 29 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-08-23
• Study Completion Date: 2025-08-31

Brief Summary

PD-1(programmed death protein 1)antibody has been to approved in patients with MSI-H/dMMR advanced cancer and has achieved significant efficacy. It is reported that the objective response rate of Pembrolizumab and Nivolumab are 40% and 31.1% in MSI-H/dMMR (microsatellite instability-high/deficiency mismatch repair )colorectal cancer. What's more, most of the patients who had response for PD-1 antibody achieved a long duration of disease control. However, not all patients with MSI-H/dMMR was sensitive to PD-1 antibody despite it is a biomarker for PD-1 antibody treatment. There were about 50-60% of patients with MSI-H/dMMR were insensitive and we don't know why. What's more, it's reported that tumor mutation burden (TMB) may be another biomarker of response to PD-1 therapy. COX (cyclooxygenase)inhibitor has been proved to prevent adenomas in colorectal and it is safe for most of the patients. Preclinical models also showed that COX inhibitor could act with PD-1 antibody in mice and control disease progress. So, this study aims to evaluated efficacy and safety of combination of PD-1 antibody and COX inhibitor in patients with MSI-H/dMMR or high tumor mutation burden colorectal cancer.

Detailed Description

This is a single arm, phase two study. Eligible patients with advanced MSI-H/dMMR colorectal cancer were assigned to receive BAT1306 plus COX inhibitor. All patients will receive the study regimen every 3 weeks. Chest/abdomen/pelvic CT with IV contrast will be performed to assess clinical response.

Conditions

Colorectal Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

PD-1 antibody + cox inhibitor

BAT1306 + aspirin(celebrex when there is contraindication to aspirin) on day 1-21 every three weeks

Group Type: EXPERIMENTAL

PD-1 antibody + cox inhibitor

Intervention Type: DRUG

BAT1306 100mg /pembrolizumab 200mg on day 1 + aspirin 200mg oral (celebrex 400mg oral when there is contraindication to aspirin) on day 1-21 every three weeks

Contraindication to aspirin :

Allergic or intolerance to aspirin; With peptic ulcers; With hemophilia or other bleeding tendencies; Have the gentic disease glucose-6 phosphate dehydrogenase deficiency.

Interventions

PD-1 antibody + cox inhibitor

BAT1306 100mg /pembrolizumab 200mg on day 1 + aspirin 200mg oral (celebrex 400mg oral when there is contraindication to aspirin) on day 1-21 every three weeks

Contraindication to aspirin :

Allergic or intolerance to aspirin; With peptic ulcers; With hemophilia or other bleeding tendencies; Have the gentic disease glucose-6 phosphate dehydrogenase deficiency.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Signed informed consent; able to comply with study and/or follow- up procedures;

2. Age:18-75 years old;

3. Histological or cytological documentation of colorectal cancer;

4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

5. There must be documentation by CT scan, MRI, or intraoperative palpation that tumor is unresectable;

6. Have had at least one lines of chemotherapy fail or refuse to receive chemotherapy;

7. Histologically confirmed metastatic or primary colorectal cancer as dMMR/MSI-H or whole exon sequence confirmed tumor mutation burden higher than 1000;

8. Adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment: Hemoglobin (Hb) ≥ 90g/ L, absolute neutrophil count (ANC) ≥ 1.5×109/ L, platelet count ≥ 100×109/ L; Total bilirubin ≤ 1.5×the upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 ×ULN; Serum creatinine ≤1.5×the ULN.

Exclusion Criteria

1. Previous treatment with other therapy targeting T-cell costimulation or immune checkpoint pathways;

2. Active, known, or suspected autoimmune disease (except for type 1 diabetes mellitus, residual hypothyroidism due to autoimmune condition requiring only hormone replacement, or conditions not expected to recur in the absence of an external trigger);

3. A previous cancer active within the previous 5 years;

4. Subjects with known allergy to the study drugs or to any of its excipients;

5. Significant cardiovascular disease including unstable angina or myocardial infarction within 6 months before initiating study treatment;

6. Heart failure grade III/IV (NYHA-classification);

7. Patients with active infection within 1 week before enrollment (infection caused by fever above 38 °C);

8. Patients with severe lung disease (interstitial pneumonia, pulmonary fibrosis, severe emphysema);

9. Patients with active gastrointestinal bleeding;

10. Patients with serious complications (intestinal obstruction, renal insufficiency, hepatic insufficiency, cerebrovascular disorders);

11. Psychiatric disease or a history of central nervous system disease that affects clinical treatment;

12. Receive other anti-tumor treatments (including anti-tumor immunotherapy, interventional therapy and intra-serosal injection of anti-tumor drugs) or participate in other interventional clinical trials within two weeks before enrollment;

13. Breast- feeding or pregnant women;

14. Lack of effective contraception;

15. The investigator determined that the patient was not eligible for this clinical trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sun Yat-sen University

OTHER

Sponsor Role: lead

Responsible Party

Yanhong Deng

professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Yanhong Deng, M.D.

Role: PRINCIPAL_INVESTIGATOR

Sixth Affiliated Hospital, Sun Yat-sen University

Locations

Gastrointestinal Hospital, Sun Yat-sen University

Guangzhou, Guangdong, China

Site Status: RECRUITING

The Sixth Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, China

Site Status: RECRUITING

Countries

China

Central Contacts

Yanhong Deng, M.D.

Role: CONTACT

dengyanh@mail.sysu.edu.cn

008613925106525

Facility Contacts

Yanghong Deng, PhD

Role: primary

dengyanh@mail.sysu.edu.cn

008613925106525

Yanhong Deng, M.D.

Role: primary

dengyanh@mail.sysu.edu.cn

008613925106525

References

Wu Z, Zhang Y, Cheng Y, Li J, Li F, Wang C, Shi L, Qin G, Zhan W, Cai Y, Xie X, Ling J, Hu H, Zhang J, Deng Y. PD-1 blockade plus COX inhibitors in dMMR metastatic colorectal cancer: Clinical, genomic, and immunologic analyses from the PCOX trial. Med. 2024 Aug 9;5(8):998-1015.e6. doi: 10.1016/j.medj.2024.05.002. Epub 2024 May 24.

Reference Type: DERIVED

PMID: 38795703 (View on PubMed)

Other Identifiers

GIHSYSU13

Identifier Type: -

Identifier Source: org_study_id